Using ‘Big’ For Good In The COVID-19 Challenge
Johnson & Johnson, among world’s largest health care groups, explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.
You may also be interested in...
Medtechs Drive To Keep The Status Quo In A Year Like No Other
The performances of the leading medtechs in the first year of the COVID-19 pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management skills and planning.
Into 2021 Medtechs Prioritize Third-Wave Coronavirus Readiness
Coronavirus has definitively changed health care delivery and the perceptions of health technologies and digital ecosystems. Industry will need to adjust to the aftermath of COVID-19, take opportunities and learn lessons from 2020 or 2021 could be every inch as challenging.
UK Updates Guidance To Reflect EU Medtech Extensions
The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.